TY - JOUR
T1 - Acetaminophen-induced toxicity to human epidermoid cell line A431 and hepatoblastoma cell line hep G2, in vitro, is diminished by silymarin
AU - Shear, Neil H.
AU - Malkiewicz, Izabella M.
AU - Klein, Dwora
AU - Koren, Gideon
AU - Randor, Samuel
AU - Neuman, Manuela G.
PY - 1995
Y1 - 1995
N2 - The skin and liver may be targets for cytotoxicity induced by oxidative drug metabolites. We used human epidermoid A431 cells and human hepatoblastoma Hep G2 cells as the experimental model. The aim of the study was to investigate and evaluate the effect of silymarin on acetaminophen (APAP)-induced toxicity under controlled conditions. Silymarin is known to be a potent antioxidant that diminishes toxicity induced by a variety of other hepatotoxins (e.g. Amanita phaloides, algae»s toxins, carbon tetrachloride). Glutathione (GSH) depletion was enhanced by adding to the medium buthionine sulfoximine [L-buthionine-(SR)-sulfoximine, BSO]. Cells were incubated with high-concentration 5-20 mM APAP or α-(minimum essential medium for 2-24 h to evaluate the drug»s ability to reduce cytoviability. Viability was then quantitated by metabolism of the tetrazolium dyes (MTT) and neutral red (NR). Cytoviability was 100% for controls. For Hep G2 treated for 24 h with 20 mM, APAP viability was 56.0% by MTT and 62.5% by NR. BSO-treated cells showed an enhanced cytotoxicity, determined by both assays. Administration of 0.5 mM silymarin reduced cytotoxicity significantly. In A431 cells, treatment with 20 mM APAP reduced viability by 57% (MTT) and 69% (NR) versus control (100%). BSO further decreased viability. Since incubation with silymarin showed significant protection against APAP toxicity, it can be considered a cytoprotective agent in this in vitro model of drug toxicity. GSH concentrations in both cell lines decrease significantly after exposure to 20 mM APAP, or 0.5 mM versus control (p < 0.05), and increased (p < 0.001) if incubated with APAP and silymarin. The protective effect could be through mitochondrial membrane stabilization and/or an increase in available GSH.
AB - The skin and liver may be targets for cytotoxicity induced by oxidative drug metabolites. We used human epidermoid A431 cells and human hepatoblastoma Hep G2 cells as the experimental model. The aim of the study was to investigate and evaluate the effect of silymarin on acetaminophen (APAP)-induced toxicity under controlled conditions. Silymarin is known to be a potent antioxidant that diminishes toxicity induced by a variety of other hepatotoxins (e.g. Amanita phaloides, algae»s toxins, carbon tetrachloride). Glutathione (GSH) depletion was enhanced by adding to the medium buthionine sulfoximine [L-buthionine-(SR)-sulfoximine, BSO]. Cells were incubated with high-concentration 5-20 mM APAP or α-(minimum essential medium for 2-24 h to evaluate the drug»s ability to reduce cytoviability. Viability was then quantitated by metabolism of the tetrazolium dyes (MTT) and neutral red (NR). Cytoviability was 100% for controls. For Hep G2 treated for 24 h with 20 mM, APAP viability was 56.0% by MTT and 62.5% by NR. BSO-treated cells showed an enhanced cytotoxicity, determined by both assays. Administration of 0.5 mM silymarin reduced cytotoxicity significantly. In A431 cells, treatment with 20 mM APAP reduced viability by 57% (MTT) and 69% (NR) versus control (100%). BSO further decreased viability. Since incubation with silymarin showed significant protection against APAP toxicity, it can be considered a cytoprotective agent in this in vitro model of drug toxicity. GSH concentrations in both cell lines decrease significantly after exposure to 20 mM APAP, or 0.5 mM versus control (p < 0.05), and increased (p < 0.001) if incubated with APAP and silymarin. The protective effect could be through mitochondrial membrane stabilization and/or an increase in available GSH.
KW - A431
KW - Acetaminophen
KW - Cytoprotection
KW - Flavonoids
KW - Hep G2
KW - Human epidermoid cell line
KW - Human hepatoblastoma cell line
KW - In vitro cytotoxicology
KW - Silymarin
KW - Target organ toxicity
UR - http://www.scopus.com/inward/record.url?scp=0028799147&partnerID=8YFLogxK
U2 - 10.1159/000211359
DO - 10.1159/000211359
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 8688194
AN - SCOPUS:0028799147
SN - 1660-5527
VL - 8
SP - 279
EP - 291
JO - Skin Pharmacology and Physiology
JF - Skin Pharmacology and Physiology
IS - 6
ER -